ADCY9 SNP Markers for CETP Inhibitor Response Stratification

Solution Overview

Problem

Existing CETP inhibitor drugs for treating cardiovascular disorders show heterogeneous patient responses and safety concerns, necessitating a need for biomarkers to predict therapeutic efficacy and risk of adverse events.

Innovation Solution

Genotyping methods to identify specific single nucleotide polymorphisms (SNPs) in the ADCY9 gene, such as rs11647778, to predict individual responses to HDL-raising agents like CETP inhibitors, allowing for personalized treatment strategies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If CETP inhibitor drugs are administered to treat cardiovascular disorders, then HDL cholesterol concentration increases, but patient responses are heterogeneous and safety concerns arise

Engineering Contradiction:

ImproveHDL cholesterol concentrationVSAvoidtherapeutic efficacy

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent applies preliminary action by performing genotyping for specific SNPs (rs11647778, rs1967309, rs2238448) before administering CETP inhibitor therapy. This allows identification of patients with genotypes predictive of favorable response, ensuring that only suitable candidates receive the treatment. The genotyping is performed in advance to stratify the patient population, thereby improving reliability of therapeutic efficacy while maintaining the HDL-raising effect.

Inventive Principle:

Principle #10Preliminary action

2Quantity of substance

If CETP inhibitor drugs are administered to treat cardiovascular disorders, then HDL cholesterol concentration increases, but adverse events occur

Engineering Contradiction:

ImproveHDL cholesterol concentrationVSAvoidadverse events

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by performing genotyping for specific SNPs (rs11647778, rs1967309, rs2238448) before administering CETP inhibitor therapy. This allows identification of patients with genotypes predictive of favorable response, ensuring that only suitable candidates receive the treatment. The genotyping is performed in advance to stratify the patient population, thereby improving reliability of therapeutic efficacy while maintaining the HDL-raising effect.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If genetic testing is performed to identify responsive patients, then treatment efficacy improves, but diagnostic complexity increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoiddiagnostic complexity

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent applies local quality by focusing genetic testing on specific, predefined SNP locations (rs11647778 in ADCY9 gene, rs1967309 in ADCY9 gene, rs2238448 in ADCY9 gene) rather than performing comprehensive genomic analysis. This targeted approach to local genetic regions maintains high diagnostic accuracy for predicting CETP inhibitor response while significantly reducing the complexity and cost of genetic testing compared to whole-genome approaches.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12371748B2Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent

Publication Date: 2025.07.29 F HOFFMANN LA ROCHE INC

AI summary

Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.